TOP TEN perturbations for 44790_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 44790_s_at
Selected probe(set): 219471_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 44790_s_at (219471_at) across 6673 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):7.6969748
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):7.6279745
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):4.9544554
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-4.632509
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

OPM-1 / MM1.S

Relative Expression (log2-ratio):4.598051
Number of Samples:4 / 4
Experimental OPM-1
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control MM1.S
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

precursor-B-ALL study 3 (E2A-PBX1) / precursor-B-ALL study 3 (TEL-AML1)

Relative Expression (log2-ratio):-4.5497875
Number of Samples:6 / 15
Experimental precursor-B-ALL study 3 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (TEL-AML1)

Relative Expression (log2-ratio):-4.440013
Number of Samples:2 / 21
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control precursor-B-ALL study 2 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-4.3680983
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):4.2064285
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):-4.104186
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.